Wellington Management Group LLP Acquires 29,500 Shares of TransMedics Group, Inc. $TMDX

Wellington Management Group LLP boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 6.1% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 515,973 shares of the company’s stock after buying an additional 29,500 shares during the period. Wellington Management Group LLP’s holdings in TransMedics Group were worth $34,271,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMDX. Candriam S.C.A. lifted its holdings in TransMedics Group by 45.4% in the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after purchasing an additional 49,580 shares during the last quarter. Emerald Investment Advisers LLC bought a new stake in TransMedics Group during the 2nd quarter valued at approximately $2,023,000. Deutsche Bank AG acquired a new stake in shares of TransMedics Group in the second quarter worth $14,415,000. Regency Capital Management Inc. DE acquired a new stake in TransMedics Group in the 1st quarter worth $2,172,000. Finally, Geneos Wealth Management Inc. acquired a new stake in TransMedics Group during the first quarter worth about $3,045,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX stock opened at $89.98 on Friday. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The firm’s 50 day moving average is $80.14 and its 200-day moving average is $92.21. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of 23.13 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same period in the prior year, the business earned $0.92 EPS. The business’s revenue for the quarter was up 20.7% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of recent research reports. Stifel Nicolaus lifted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Needham & Company LLC decreased their price objective on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. UBS Group lowered their price objective on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Piper Sandler restated an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $124.18.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.